Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals SBC expense by Quarter
SBC expense — Selling, general and administrative ($M) ($M)
Vertex Pharmaceuticals SBC expense: $62M in Q2 2026, down 4.9% from a year earlier.
Latest, Q2 2026
62
Period ended Jun 30, 2026
Change on a year earlier
-4.9%
65.2 in Q2 2025
History
36 quarters
Since Q1 2017
Sources
31
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Stock-based Compensation).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SBC expense — Selling, general and administrative ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 62 | -4.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 61.5 | -3.0% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 54.7 | -19.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 76.1 | +6.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 65.2 | +17.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 63.4 | -10.3% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 67.5 | -19.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 71.7 | +49.1% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 55.3 | +28.6% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 70.7 | +60.0% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | 83.5 | +103.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 48.1 | -9.6% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 43 | +2.4% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 44.2 | -7.3% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | 41.1 | -8.7% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 53.2 | +31.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 42 | +4.0% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 47.7 | +16.3% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | 45 | +23.3% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 40.4 | +7.7% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 40.4 | -11.2% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 41 | -1.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 36.5 | +9.3% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | 37.5 | +18.7% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 45.5 | +40.0% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2020 | Mar 31, 2020 | 41.7 | +27.5% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 31, 2019 | 33.4 | – | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2019 | Sep 30, 2019 | 31.6 | +0.6% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2019 | Jun 30, 2019 | 32.5 | +9.8% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 32.7 | +13.5% | Form 10-Q (filed 2020-05-01) ↗ |
| Q3 2018 | Sep 30, 2018 | 31.4 | +13.8% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 29.6 | +2.8% | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2018 | Mar 31, 2018 | 28.8 | +19.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q3 2017 | Sep 30, 2017 | 27.6 | – | Form 10-Q (filed 2018-10-25) ↗ |
| Q2 2017 | Jun 30, 2017 | 28.8 | – | Form 10-Q (filed 2018-07-26) ↗ |
| Q1 2017 | Mar 31, 2017 | 24.1 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals SBC expense ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-exp-sga
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.